What is PathAI?
Headquartered in Boston, Massachusetts, PathAI operates at the intersection of digital pathology and artificial intelligence. The company provides a sophisticated platform designed to assist researchers and clinicians in the identification and analysis of disease markers with unprecedented precision. By automating and augmenting the pathology workflow, PathAI enables life sciences organizations to optimize drug discovery and clinical trial efficacy. The firm's market position is defined by its ability to integrate seamlessly into existing laboratory infrastructures, providing actionable insights that drive the development of personalized therapeutic strategies. As the demand for data-driven healthcare solutions grows, PathAI remains a pivotal partner for pharmaceutical companies seeking to navigate the complexities of modern oncology and immunology.
How much funding has PathAI raised?
PathAI has raised a total of $180.2M across 3 funding rounds:
Other Financing Round
$4.2M
Series A
$11M
Series C
$165M
Other Financing Round (2016): $4.2M with participation from Refactor Capital, 8VC, Fairhaven Capital, and Pillar VC
Series A (2017): $11M led by Refactor Capital, 8VC, Pillar VC, General Catalyst, Danhua Capital, and KdT Ventures
Series C (2021): $165M supported by Bristol-Myers Squibb, Merck Global Health Innovation Fund, Biospring Partners, Adage Technologies, Labcorp, General Catalyst, Refactor Capital, D1 Capital Partners, General Atlantic, Polaris Partners, 8VC, Kaiser Permanente, KdT Ventures, and Tiger Global Management
Key Investors in PathAI
General Catalyst
A venture capital firm focused on identifying and supporting transformational business opportunities across multiple sectors, leveraging deep operational experience to accelerate growth.
8VC
A leading technology investment firm that backs industry-transforming companies, with a specific focus on smart enterprise platforms in healthcare and Bio-IT.
Refactor Capital
An early-stage venture capital firm that specializes in investing in hard tech founders who are addressing fundamental human problems through innovative science.
What's next for PathAI?
With the recent strategic investment, PathAI is well-positioned to scale its operational capabilities and expand its footprint within the global biopharmaceutical ecosystem. The company is expected to prioritize the enhancement of its AI-powered research tools, focusing on deeper integration with clinical trial workflows and the expansion of its diagnostic service offerings. By fostering continued collaboration with industry giants and research institutions, PathAI aims to standardize the use of computational pathology in routine clinical practice. The focus moving forward will likely center on international market penetration and the development of new therapeutic insights, ensuring that the company remains at the forefront of the precision medicine revolution while maintaining its commitment to rigorous scientific validation and patient-centric innovation.
See full PathAI company page
